| Customization: | Available |
|---|---|
| CAS No.: | 737789-87-6 |
| Formula: | C29h27f2n7o5s |
|
Still deciding? Get samples of US$ 100/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Hangzhou Jinlan Pharm-Drugs Technology Co. Ltd.(JL Pharm) is an advanced pharmaceutical corporation with a laboratory of 1200 square meters in Nanjing city, and cooperative GMP production plants in Beljing, Jiangsu, Zhejiang, Jiangxi, Chengdrand Shandong.We can provide both CDMO technology research and development services, and a ful range of laboratory R&D and production services for raw materials and pharmaceutical intermediates to globapharmaceutical companies during which synthetic route research and development, process reearch and development and optimization, scale-up production, domestic and foreign drug registration, and industrial equipment selection, automatic control system and technical process packages.
| Product Name: | Relugolix |
| Synonyms: | TAK-385;Relugolix;Altropane;TKA-385 Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;Relugolix TAK-385;TAK-385,Relugolix;CS-2851 |
| CAS: | 737789-87-6 |
| MF: | C29H27F2N7O5S |
| MW: | 623.63 |
| EINECS: | |
| Product Categories: | API;737789-87-6 |
| Mol File: | 737789-87-6.mol |
| Melting point | 228 °C (decomp)(Solv: ethyl acetat tetrahydrofura |
| density | 1.442±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:20.0(Max Conc. mg/mL);32.1(Max Conc. mM) Ethanol:1.0(Max Conc. mg/mL);1.6(Max Conc. mM) |
| form | A crystalline solid |
| pka | 13.17±0.70(Predicted) |
| InChIKey | AOMXMOCNKJTRQP-UHFFFAOYSA-N |
| SMILES | N(C1=CC=C(C2SC3=C(C=2CN(C)C)C(=O)N(C2=NN=C(OC)C=C2)C(=O)N3CC2=C(F)C=CC=C2F)C=C1)C(NOC)=O |
| Uses | Relugolix is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment |
| Mechanism of action | The mechanism of action of relugolix is as a Gonadotropi Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion. |
| Synthesis | Relugolix is produced by the reaction of 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione and phenyl N-methoxycarbamate. |
){kind=link}